Post-Hoc Live
By Endpoints News
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Endpoints News
Category: News
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 1
Reviews: 0
Episodes: 40
Description
Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We're bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations.
Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: posthoclive@endpointsnews.com
| Episode | Date |
|---|---|
|
Makary's out: Live from the FT Summit
|
May 15, 2026 |
|
Q1 earnings recap with Endpoints News
|
May 12, 2026 |
|
Trust, MAHA, and what’s next for the CDC
|
Apr 24, 2026 |
|
The spring deals bonanza
|
Apr 10, 2026 |
|
The politics of vaccines — with former congressman Dr. Michael Burgess
|
Mar 31, 2026 |
|
Who won the Hims vs Novo feud?
|
Mar 10, 2026 |
|
Protecting US biotech from Chinese competition — with the NSCEB
|
Mar 06, 2026 |
|
Moderna vs the FDA
|
Feb 11, 2026 |
|
Hims, Novo, and a new front in the compounding wars
|
Feb 06, 2026 |
|
Post-Hoc Live, Live! at #JPM26 with Noubar Afeyan
|
Jan 20, 2026 |
|
Fewer drugs, more chaos: One year under the new FDA
|
Jan 08, 2026 |
|
Biopharma’s Winners and Losers of 2025
|
Dec 18, 2025 |
|
Reality check-ing biotech — with Derek Lowe
|
Nov 20, 2025 |
|
M&A, MFN, and the view from the UK — with the FT’s Hannah Kuchler
|
Nov 04, 2025 |
|
The plan to make more custom CRISPR therapies — w Kiran Musunuru & Rebecca Ahrens-Nicklas
|
Nov 03, 2025 |
|
The fight over Metsera
|
Nov 03, 2025 |
|
Is the biotech market…back? — with Tim Opler and John Carroll
|
Oct 15, 2025 |
|
Zooming out on AI in biopharma — with Vijay Pande
|
Oct 07, 2025 |
|
This week in Washington: TrumpRx, MFN pricing, tariffs, and more
|
Oct 01, 2025 |
|
Scott Gottlieb on what it would take to compete with China's biotech rise
|
Sep 26, 2025 |
|
Which digital health tools are worth the cost? — with Caroline Pearson
|
Sep 16, 2025 |
|
Breaking down the XBI — with Josh Schimmer
|
Sep 10, 2025 |
|
Choosing the Endpoints 11
|
Sep 03, 2025 |
|
John Maraganore and Clive Meanwell are coming out of stealth
|
Sep 02, 2025 |
|
mRNA vs MAHA — with Brett Giroir
|
Aug 12, 2025 |
|
Getting answers on tariffs, China and Trump: What we learned from Q2 earnings
|
Aug 07, 2025 |
|
Why China’s biotech boom may be unstoppable
|
Aug 01, 2025 |
|
The Sarepta mess
|
Jul 29, 2025 |
|
Sarepta’s very bad week
|
Jul 21, 2025 |
|
Drugs! In! Space! With Varda Chief Science Officer Adrian Radocea
|
Jul 17, 2025 |
|
Is China a threat, or an investment opportunity? Post-Hoc Live with Curie.Bio CEO Zach Weinberg
|
Jul 10, 2025 |
|
What we learned from RFK’s reconstructed ACIP
|
Jun 27, 2025 |
|
On the ground at BIO 2025
|
Jun 18, 2025 |
|
What happens if AI gets smarter than we are?
|
Jun 13, 2025 |
|
The fallout from RFK's gutting of ACIP: Post-Hoc Live with former CDC Director Mandy Cohen
|
Jun 12, 2025 |
|
Is biotech sentiment as bad as it seems?
|
Jun 12, 2025 |
|
"Most Favored Nation": The White House plan to cut drug prices
|
Jun 12, 2025 |
|
What will Vinay Prasad's CBER look like?
|
Jun 12, 2025 |
|
How pharma is reacting to ‘Liberation Day’
|
Jun 12, 2025 |
|
Trailer
|
Jun 11, 2025 |